203 related articles for article (PubMed ID: 11819752)
1. Effects of Taxotere on invasive potential and multidrug resistance phenotype in pancreatic carcinoma cell line SUIT-2.
Liu B; Staren E; Iwamura T; Appert H; Howard J
World J Gastroenterol; 2001 Feb; 7(1):143-8. PubMed ID: 11819752
[No Abstract] [Full Text] [Related]
2. Mechanisms of taxotere-related drug resistance in pancreatic carcinoma.
Liu B; Staren ED; Iwamura T; Appert HE; Howard JM
J Surg Res; 2001 Aug; 99(2):179-86. PubMed ID: 11469885
[TBL] [Abstract][Full Text] [Related]
3. Taxotere resistance in SUIT Taxotere resistance in pancreatic carcinoma cell line SUIT 2 and its sublines.
Liu B; Staren E; Iwamura T; Appert H; Howard J
World J Gastroenterol; 2001 Dec; 7(6):855-9. PubMed ID: 11854916
[TBL] [Abstract][Full Text] [Related]
4. Differential cytotoxic effects of docetaxel in a range of mammalian tumor cell lines and certain drug resistant sublines in vitro.
Hill BT; Whelan RD; Shellard SA; McClean S; Hosking LK
Invest New Drugs; 1994; 12(3):169-82. PubMed ID: 7896535
[TBL] [Abstract][Full Text] [Related]
5. Chemistry and chemical biology of taxane anticancer agents.
Miller ML; Ojima I
Chem Rec; 2001; 1(3):195-211. PubMed ID: 11895119
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of endothelial cell function in vitro and angiogenesis in vivo by docetaxel (Taxotere): association with impaired repositioning of the microtubule organizing center.
Hotchkiss KA; Ashton AW; Mahmood R; Russell RG; Sparano JA; Schwartz EL
Mol Cancer Ther; 2002 Nov; 1(13):1191-200. PubMed ID: 12479700
[TBL] [Abstract][Full Text] [Related]
7. Interaction of docetaxel ("Taxotere") with human P-glycoprotein.
Shirakawa K; Takara K; Tanigawara Y; Aoyama N; Kasuga M; Komada F; Sakaeda T; Okumura K
Jpn J Cancer Res; 1999 Dec; 90(12):1380-6. PubMed ID: 10665657
[TBL] [Abstract][Full Text] [Related]
8. Survival of docetaxel-resistant prostate cancer cells in vitro depends on phenotype alterations and continuity of drug exposure.
Makarovskiy AN; Siryaporn E; Hixson DC; Akerley W
Cell Mol Life Sci; 2002 Jul; 59(7):1198-211. PubMed ID: 12222966
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and cytotoxicity of 2alpha-amido docetaxel analogues.
Fang WS; Liu Y; Liu HY; Xu SF; Wang L; Fang QC
Bioorg Med Chem Lett; 2002 Jun; 12(11):1543-6. PubMed ID: 12031338
[TBL] [Abstract][Full Text] [Related]
10. Multidrug resistance reversal activity of taxoids from Taxus cuspidata in KB-C2 and 2780AD cells.
Kobayashi J; Shigemori H; Hosoyama H; Chen Z; Akiyama S; Naito M; Tsuruo T
Jpn J Cancer Res; 2000 Jun; 91(6):638-42. PubMed ID: 10874217
[TBL] [Abstract][Full Text] [Related]
11. Comparison of paclitaxel and docetaxel (Taxotere) in gynecologic and breast cancer cell lines with the ATP-cell viability assay.
Untch M; Untch A; Sevin BU; Angioli R; Perras JP; Koechli O; Averette HE
Anticancer Drugs; 1994 Feb; 5(1):24-30. PubMed ID: 7910494
[TBL] [Abstract][Full Text] [Related]
12. Selective drug resistant human osteosarcoma cell lines.
Burns BS; Edin ML; Lester GE; Tuttle HG; Wall ME; Wani MC; Bos GD
Clin Orthop Relat Res; 2001 Feb; (383):259-67. PubMed ID: 11210963
[TBL] [Abstract][Full Text] [Related]
13. Cytosine arabinoside (ara-C) resistance confers cross-resistance or collateral sensitivity to other classes of anti-leukemic drugs.
Martin-Aragon S; Mukherjee SK; Taylor BJ; Ivy SP; Fu CH; Ardi VC; Avramis VI
Anticancer Res; 2000; 20(1A):139-50. PubMed ID: 10769646
[TBL] [Abstract][Full Text] [Related]
14. Differential impact of Raf-1 kinase activity on tumor cell resistance to paclitaxel and docetaxel.
Britten RA; Klein K
Anticancer Drugs; 2000 Jul; 11(6):439-43. PubMed ID: 11001384
[TBL] [Abstract][Full Text] [Related]
15. Comparative effects of taxol and Taxotere on two different human carcinoma cell lines.
Garcia P; Braguer D; Carles G; el Khyari S; Barra Y; de Ines C; Barasoain I; Briand C
Cancer Chemother Pharmacol; 1994; 34(4):335-43. PubMed ID: 7913421
[TBL] [Abstract][Full Text] [Related]
16. Semi-synthesis of an O-glycosylated docetaxel analogue.
Nikolakakis A; Haidara K; Sauriol F; Mamer O; Zamir LO
Bioorg Med Chem; 2003 Apr; 11(7):1551-6. PubMed ID: 12628678
[TBL] [Abstract][Full Text] [Related]
17. Taxane sensitivity of ovarian carcinoma in vitro.
Engblom P; Rantanen V; Kulmala J; Heiskanen J; Grenman S
Anticancer Res; 1997; 17(4A):2475-9. PubMed ID: 9252666
[TBL] [Abstract][Full Text] [Related]
18. Multidrug resistance phenotype and paclitaxel (Taxol) sensitivity in human renal carcinoma cell lines of different histologic types.
Reinecke P; Schmitz M; Schneider EM; Gabbert HE; Gerharz CD
Cancer Invest; 2000; 18(7):614-25. PubMed ID: 11036469
[TBL] [Abstract][Full Text] [Related]
19. Differences in docetaxel and paclitaxel activity in resistant tumor cells which express MRP: need of comparative clinical trials in resistant patients.
D'Incalci M
Ann Oncol; 1997 Dec; 8(12):1183-4. PubMed ID: 9496382
[No Abstract] [Full Text] [Related]
20. In vitro antiproliferative activity of docetaxel (Taxotere), paclitaxel (Taxol) and cisplatin against human tumour and normal bone marrow cells.
Braakhuis BJ; Hill BT; Dietel M; Kelland LR; Aapro MS; Zoli W; Lelieveld P
Anticancer Res; 1994; 14(1A):205-8. PubMed ID: 7909419
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
